Rilimogene galvacirepvec: Phase II started

Bavarian Nordic said the NCI began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate subcutaneous ProstVac given on days 0, 14, 28, 56, 84, 112 and 140 in about 90 patients undergoin...